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ABBREVIATION 
 AAH  - Atypical adenomatous hyperplasia 
 ASAP - Atypical small acinar proliferation 
 BCH  - Basal cell hyperplasia 
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                                             INTRODUCTION 
 Benign prostatic hyperplasia and prostatic adenocarcinoma are the 
two principle conditions involving prostate among elderly men in urology 
practice. It accounts for more than 90% of all prostatic diseases. The 
prostate undergoes significant growth during fetal development, puberty 
and in most men during late middle age. At the end of puberty the prostate 
reaches approximately 26 g. 
 Benign prostatic hyperplasia occurs in individuals with intact testis 
and it is an androgen dependent disorder. The clinical incidence of this 
disease is only 8% during fourth decade, but it reaches 50% in the fifth 
decade and 75% in the eighth decade. BPH remains one of the major cause 
of obstructive urologic symptoms of patients coming to the urology out 
patient department. Transurethral resection of prostate remains the gold 
standard of treatment against which all other treatments of benign prostatic 
hyperplasia are measured. It is one of the most common procedure 
performed by urologists. After the introduction of screening for prostatic 
specific antigen, transrectal ultrasound and MRI prostate trucut needle 
biopsy became one of the most common urologic procedure to detect 
prostatic carcinoma. 
 In routine surgical pathology practice, making a morphological 
diagnosis of prostatic lesions, especially separating benign from malignant 
lesions is relatively straightforward. However, there are several glandular 
and stromal proliferations and normal histoanatomical structures which 
may be mistaken for malignancy if one is not aware of the key histological 
features. It is very difficult to interpret these lesions in small tissue samples 
such as received in trucut needle biopsies. 
 For practicing pathologists and urologists there are currently two 
main issues in prostate pathology, one is the identification of prognostic 
factors that predict the outcome of individual patients with prostatic 
carcinoma. The other involves the early detection of prostatic carcinoma in 
the preinvasive phase. Hence, understanding the morphology of precursor 
or preinvasive lesions has become increasingly important. 
 The relationship between prostatic carcinoma and premalignant 
lesions of the prostate is a subject of great interest analyzed in numerous 
publications. Despite many studies conducted over this area each year, 
there were still important questions remain about the cause and prevention 
of prostate cancer. 
 Inspite of significant advances in the early detection of prostatic 
carcinoma by transrectal ultrasound, serum levels of prostatic specific 
antigen, the major diagnostic problem with the tumour pathology is making 
a diagnosis between adenocarcinoma and benign small acinar 
proliferations. 
AIMS 
¾ To find out the association of hyperplastic, metaplastic, inflammatory 
and premalignant lesions in transurethral resection of prostate, trucut 
needle and open prostatectomy specimens for a two year period from 
January 2004 to December 2005. 
¾ To analyze the histological types of associated lesions in benign 
prostatic hyperplasia and prostatic adenocarcinoma. 
¾ To evaluate the significance of these lesions in correlation with 
histological type and grading of prostatic adenocarcinoma. 
 REVIEW OF LITERATURE 
 Prostate is a pyramidal fibromuscular gland which surrounds the 
prostatic urethra from the bladder base to the membranous urethra and is 
itself surrounded by a thin but tough connective tissue capsule. 
 It lies at a low level in the lesser pelvis, behind the inferior border of 
the symphysis pubis and pubic arch, below the neck of the urinary bladder 
and anterior to the rectal ampulla through which it can be palpated1. 
 Anatomically prostate is divided into five lobes anterior, posterior, 
median and two lateral lobes. The contemporary classification of the 
prostate into different zones was based on the work of Mc Neal. He divided 
prostate into peripheral zone (PZ), which lies mainly posteriorly and from 
which most carcinomas arise and a central zone (CZ), which lies posterior 
to the urethral lumen and above the ejaculatory ducts. There is also a 
periurethral and transitional zone (TZ) which is the most common location 
of benign prostatic hyperplasia2. 
 The understanding of anatomical lobes and the surgical zones are 
essential in interpretation of prostatic biopsy specimens sent in Trans 
urethral resection of prostate (TURP) and trucut needle biopsy. 
 The prostate is supplied by branches from the inferior vesical, 
internal pudental and middle rectal arteries. It drains into vesical and 
internal illiac veins. Lymphatics from the prostate drain chiefly into internal 
illiac, sacral and obturator nodes. The prostate has an abundant nerve 
supply from the inferior hypogastric plexus1. 
 As stated in the introduction, benign prostatic hyperplasia occurs in 
men over the age of 50 yrs, and by the age of 60 yrs 50% men have 
histological evidence of benign prostatic hyperplasia. 
 Benign prostatic hypertrophy is a commonly used term. The term 
`nodular hyperplasia' proposed by Moore in 1936 in his classic study or the 
term `adenomyomatous hyperplasia', aptly describes the lesion. 
 BPH begins as micronodules in the transitional zone. They grow and 
coalesce to form macronodules around the inferior margin of the 
preprostatic urethra, just above the verumontanum. Macronodules in turn 
compress the surrounding normal tissue of the peripheral zone postero 
inferiorly thereby creating a `false capsule' around the hyperplastic tissue, 
which coincidentally provides a plane of cleavage for surgical enucleation 
of hyperplastic tissue by either transurethral resection of prostate or open 
prostatectomy. 
 BPH and adenocarcinoma arise in the men of the same age group. 
There are many associated epithelial and stromal lesions in benign prostatic 
hyperplasia which quite often mimic the histomorphology of 
adenocarcinoma. Hence, a depth of knowledge of these lesions is essential 
for correct histological diagnosis, clinical evaluation and followup. 
 Following is the working classification3 of hyperplastic, metaplastic 
& tumour like lesions of prostate. 
CLASSIFICATION  
Epithelial lesions 
Hyperplasia 
 • Benign nodular hyperplasia 
 • Basal cell hyperplasia 
 • Postatrophic hyperplasia 
 • Mesonephric remnant hyperplasia 
 • Clear cell cribriform hyperplasia 
 • Verumontanum mucosal gland hyperplasia 
Metaplastic changes 
 • Squamous cell metaplasia 
 • Transitional cell metaplasia 
 • Mucinous metaplasia 
Tumour like lesions 
 • Atrophy 
 • Sclerosing adenosis 
 • Nephrogenic adenoma of prostatic urethra 
 • Prostatic type urethral polyp 
 • Seminal vesicle/Ejaculatory duct/Cowper's gland/paraganglia 
in prostate samples 
 • Cysts 
 • Amyloidosis 
 • Calculi/calcification/cartilage 
Stromal lesions 
 • Prostatitis 
 • Stromal hyperplasia/nodule 
 • Leiomyoma 
 • Fibroadenoma like lesion/phyllodes type tumor 
 • Post operative spindle cell nodule 
 • Inflammatory myofibroblastic tumor 
 • Blue nevus/prostatic epithelial pigment 
Premalignant lesions 
 • Prostatic intraepithelial neoplasia 
 • Atypical adenomatous hyperplasia 
EPITHELIAL AND STROMAL LESIONS 
 In 1936, Moore et al.4 in his studies published a detailed account of 
the histological features of the normal and involutional prostate gland based 
on a study of 678 prostate glands. He suggested atrophy as a physiological 
and age related phenomenon. He described the presence of luminal 
acidophilic secretions in atrophy. 
 Post atrophic hyperplasia was first illustrated and published by 
Moore4 in 1936 although he did not make any special reference to it in the 
text. This was followed by descriptions by Totten et al. in 1953, but they 
referred to this process as lobular hyperplasia. The term `post atrophic 
hyperplasia' and `post sclerotic hyperplasia' were coined by Frank et al. in 
1954, who proposed this lesion as a precursor to prostatic adenocarcinoma. 
But later studies did not establish such a relationship between post atrophic 
hyperplasia and prostatic adenocarcinoma. 
 In 1999 Mahul B.Amin, Pheroze Tamboli, Muralivarma and John 
R.Srigley5 studied 56 needle biopsy specimens containing 68 foci to 
ascertain the morphologic spectrum of postatrophic hyperplasia. Age of the 
patient ranged from  49 to 85 yrs. Selection of cases were restricted to those 
foci in which the process formed a small acinar proliferation atleast some of 
which raised the question of carcinoma. In this study, the prevalence of post 
atrophic atrophic hyperplasia presenting as a small acinar proliferation in 
consecutive biopsy specimens was 3.6%. 
 Basal cell hyperplasia was relatively a common lesion in 
hyperplastic prostates being examined by Young R.H. et al.6 in his studies. 
Clear cell cribriform hyperplasia of the prostate is a rare form of 
hyperplasia found in BPH. It was recognized by the world health 
organization in 1980. Gleason7 described the same lesions as a florid benign 
papillary cribriform hyperplasia in 1985. Immunoperoxidase studies 
demonstrated that the clear cells of CCCH show strong immuno reactivity 
for prostatic specific antigen and prostatic acid phosphatase. 
 Transitional cell metaplasia was studied by Yantiss R.K. Young, 
R.H.8 in 1997 and incidence was found to be 34% in 103 consecutive 
prostatic biopsy specimens studied. They were quite commonly seen in the 
transitional zone around the prostatic urethra. 
 Mucinous metaplasia was studied by Frank et al.9 in 1964. About 
155 prostate glands were studied in which whole organ sections were 
stained for mucin. They described the presence of PAS and alcianblue 
positive goblet cells with in the transitional epithelium of prostatic urethra 
and proximal prostatic ducts. Dikman and Toker et al.10 in 1973 noted the 
presence of seromucinous glands in prostatic stroma. They concluded that 
the lesion was an ectopia of minor salivary glands. 
 In 1993 David J. Grignon and Frances P.O Malley11 observed tall 
columnar mucin secreting cells in 12 cases of benign prostatic hyperplasia 
out of 1700 cases in a three year study. All cases were stained 
histochemically for mucicarmine, alcianblue and period acid schiff's. They 
documented the presence of acid mucin in the luminae of basal cell 
hyperplasia, post atrophic hyperplasia and also in some glands involved 
with transitional cell metaplasia. The presence of acidic mucin in secretory 
cells in benign lesions point to the nonspecificity of this finding in the 
diagnosis of malignancy. 
 In 1999, Nickel JC, Downey J, Young I et al.12 examined benign 
prostatic tissue sections and reported that inflammation was present in 44% 
to 100% of the prostatic tissue samples examined. 
 In 2003 Disilverio F, et al14 analyzed retrospectively 3942 cases of 
benign prostatic hyperplasia for a period of 20 years and reported a mean 
patient age of 68.85± 7.67 years. Inflammation was found in 43.1% (1700 
cases), predominantly it was a chronic inflammation. Incidence of focal 
acinar atrophy was significantly related to increase in age of the patient. 
They suggested that different histological features associated with benign 
prostatic hyperplasia were influenced by the age of the patients and volume 
of the prostate. 
 In 2005 Brian Difuccia et al.15 tried to assess the variation of 
inflammation on single/multiple needle biopsy samples taken from 
predetermined areas of prostates removed from patients with cancer. They 
concluded that the foci of inflammation were predominantly multifocal and 
diffuse and occasionally periglandular in localization. 
 Sclerosing adenosis is a prostatic lesion which has been first 
reported by Chen A Schiff in 1983 as adenomatoid tumour of prostate due 
its morphological resemblance to adenomatoid tumour. The term sclerosing 
adenosis was introduced by Young & Clement in 1987 on the basis of 
histological resemblance to sclerosing adenosis of the breast. In 1991 
Sakomoto et al.16 analyzed 263 specimens of prostate, found 5 cases of 
sclerosing adenosis with an incidence of 1.9% which was found to be 
localized to the transitional zone. 
PREMALIGNANT LESIONS 
 Two putative premalignant lesions of the prostate have been 
described. The clinical importance of recognizing these lesions is based on 
its strong association with carcinoma. Its identification in biopsy specimens 
of the prostate warrants further search for concurrent invasive carcinoma. 
They are: 
 1. Prostatic intraepithelial neoplasia (PIN) (or) 
   Ductal acinar/intra ductal dysplasia. 
 2. Atypical adenomatous hyperplasia (AAH) (or) 
   Atypical small acinar proliferation (ASAP) 
 In 1965 Mc Neal17 was the first one to describe this premalignant 
lesion, but his concept of preneoplasia was not fully embraced until 1980's. 
In 1986 Mc Neal & Bostwick17, while studying 100 specimens of prostatic 
adenocarcinoma and 100 benign prostates obtained at autopsy, noticed foci 
of PIN in 82 prostates with carcinoma and 43 benign prostates. It provided 
strong support regarding the status of PIN as a precursor lesion. 
 In 1987 Brawer et al.18 in his studies showed that there is a basal cell 
layer disruption in 56% of the cases with high grade PIN. The amount of 
disruption increased with increasing grades of PIN. 
 In 1989, there was a workshop on premalignant lesions of the 
prostate held at Bethesda Maryland and at this meeting prostatic intra 
epithelial neoplasia was adopted as a preferred term. In 1989, Troncoso et 
al.19 studied sections of prostate gland obtained from patients undergoing 
cystoprostatectomy for bladder cancer and found PIN in 89 of 100 
prostates. Most of the PIN were multifocal and high grade and they were 
most common in prostates with carcinoma than without carcinoma. 
 From the practical point of view histological grading of PIN is 
important. Originally three grades were adopted. Then two grade system 
was established on the basis of cluster analysis. In 1989 Bethesda 
Workshop investigators agreed on the grading system that described low 
and high grade PIN by incorporating the previous grade 1 as low grade and 
grades 2 & 3 into the high grade20. 
 In 1995 Montironi et al.21 attempted to standardize the morphological 
criteria for identification and grading of PIN through a bayesian belief 
network. This network is designed to distinguish between normal prostate, 
low grade PIN, high grade PIN, cribriform adenocarcinoma and large 
acinar adenocarcinoma. 
 In 1996 David G.Bostwick M.D. et al.22 in his clinical studies 
suggested PIN predates carcinoma by ten years or more and low grade PIN 
first appearing in men in their thirties. Finding of high grade PIN indicates 
the need for repeat biopsy and followup in particular, if prostatic specific 
antigen in serum is elevated. 
 In 1997 Junqi Qian, Peter Wollan, and David G.Bostwick23, studied 
195 whole mounted radical prostatectomy specimens with clinically 
localized cancer. High grade PIN was identified in 86% of cases and was 
usually multicentric in 64.5% of cases and located in the non transitional 
zone in 63% and in all zones in 36% of cases. 
 In 1997 Nagle24 RB et al. studied the progressive molecular changes 
in prostatic epithelium. Their data indicated that the dysplastic cells of PIN 
lesion and carcinomas were similar in nuclear and genomic features as well 
as protease expression. 
 In 2001, Saker WA, Partin25 AW studied cases obtained at autopsy 
revealed that highgrade PIN was found in association with cancer in 63% to 
94% of malignant and 25% to 43% of benign prostates. They suggested that 
there was a significant risk for patients with isolated highgrade PIN to have 
prostatic cancer which was confirmed by them on subsequent biopsies 
 In 2001 Allcaraz A, et al.26 analyzed 28 high grade PIN cases found 
among 57 specimens of radical prostatectomy using a FISH technique to 
study the cytogenetic alteration and suggested that high grade PIN could be 
an early form of cancer. 
 In 2004, Rekhi B, Jaswal TS, Arora B.27 studied PIN and AAH in 
ducto-acinar lining epithelium of 200 prostatectomy specimens. Out of 177 
cases of nodular hyperplasia, 53 (29.9%) showed PIN and 38 (20.3%) 
showed presence of AAH. All 6 cases of pure carcinoma revealed foci of 
PIN (100%) suggesting a stronger association of high grade PIN as the 
potent precursor of carcinoma prostate. 
 In 1986, Mc Neal28 referred atypical adenomatous hyperplasia 
(AAH) as a possible premalignant proliferation, most probably of 
carcinomas arising in the transitional zone. In 2000, Kien T.Mari et al.29 
reviewed 533 and 499 TURP specimens before and after the introduction of 
PSA screening respectively. They suggested the possibility of association 
of atypical adenomatous hyperplasia with low grade carcinoma arising 
from transitional zone and association of PIN with carcinomas arising in 
non-transitional zone. 
 Atypical adenomatous hyperplasia has been proposed as a precursor 
of prostatic adenocarcinoma of the transitional zone for the following 
reasons20. 
 i. Age peak that precedes that of PCa. 
 ii. Increased incidence in association with PCa. 
 iii. Topographic relationship with small acinar PCa. 
 iv. Increased nuclear area and diameter. 
 v. A proliferative index similar to that of small acinar PCa. 
 vi. An occasional cases with genetic alterations. 
 The term `adenosis' was suggested to replace `atypical adenomatous 
hyperplasia'. This has not been accepted and `atypical' has been retained to 
indicate the unusual pattern of small acinar formations that characterize 
AAH. Currently, the term atypical adenomatous hyperplasia is replaced by 
`Atypical small acinar proliferation' (ASAP). 
 Previously the data were insufficient to conclude atypical 
adenomatous hyperplasia as a premalignant lesion. In 2005 Courtenay 
K.Moore et al.30 in their study of 1,188 cases selected 105 cases of which 
33 had HGPIN and 72 had ASAP. They applied a extended biopsy scheme 
over the patients diagnosed with high grade PIN and atypical small acinar 
proliferation. According to that study in the first repeat biopsy, only 1 of 22 
(4.5%) men with previous HG PIN had cancer while 19 of 53 (36%) with a 
history of ASAP were found to have cancer. In the second repeat biopsy, 
none of the 11 men previously diagnosed with HG PIN had cancer. But 3 of 
19 (16%) men with ASAP had cancer. 
 Hence, they suggested that highgrade PIN does not warrant a repeat 
biopsy and atypical small acinar proliferation continues to be associated 
with a high risk of cancer and requires atleast one repeat biopsy using 
extended biopsy scheme. 
PROSTATIC ADENOCARCINOMA 
 Adenocarcinoma of prostate is the most common malignancy 
encountered in the urologic practice and is one of the leading cause of 
cancer death in men. Prostatic carcinoma is rare before 40 years of age, but 
the incidence rises quickly thereafter. 
 In 1817 Langstaff, et al.31 were the earliest to recognize this entity; 
although at that time its differentiation from other enlargements of the 
prostate was imperfectly understood. 
 In 1900, Albarran and Halle et al. examined 100 cases and stated that 
adenocarcinoma prostate constituted 4% of all prostatic enlargements and 
defined adenocarcinoma as a lesion in between ordinary hypertrophy of old 
age and true prostate cancer. 
 Important questions always remain about the cause and prevention of 
prostate cancer, but many literature reviews show the significant advances 
in the understanding of premalignant epithelial lesions as well as clinching 
clinical techniques such as transrectral ultrasound and serum prostatic 
specific antigen levels enhance the early detection of prostatic cancer. 
Histological grading 
 Historically, atleast 40 different classifications for prostatic 
carcinomas have been published, but only 19 have been examined closely 
for their prognostic significance. Broder et al.32 is the pioneer who 
introduced the first grading system in 1925 in an attempt to estimate the 
malignant potential of cancer. It was based on degree of glandular 
differentiation, cell morphology, mitotic activity and degree of 
invasiveness. 
 In 1966 Gleason et al.33 suggested a grading system which has been 
accepted by most of the urologists. He utilized glandular differentiation and 
growth pattern in relation to stroma to identify tumor grades. 
 M.D. Anderson et al.3 grading system is based only on percentage of 
gland formation and tumour cell morphology is not taken into account. 
 In 1975 Mostofi et al.34 proposed another grading system which was 
based on pattern of glandular differentiation and degree of nuclear 
anaplasia. It consists of three grades. 
 In 1980 Gaeta JF et al.35 studied 19 cases of prostatic carcinoma and 
established a four grade system that combined the glandular pattern and 
nuclear morphology. This study showed a linear correlation between 
survival and mortality index. 
 In 1982 Brawn PN et al.36 described a grading system based on 
percentage of tumour that shows differentiated (gland forming) and 
undifferentiated (non-gland forming) components. This grading system was 
also shown to correlate well with survival. 
 Galle et al.37 compared the prognostic accuracy of five grading 
systems-Broders, Gleason, M.D.Anderson, Mostofi, Mostofi-schroeder in 
50 prostatectomy specimens. They concluded that Gleason system had the 
lowest predictive ability. Whereas Broders and Mostofi-Schroeder systems 
had reasonable predictive ability. 
 Inspite of all these problems of intra and inter observer variability, 
imprecise predictive value, the `Gleason Grading System' remains the `de 
factor standard' for grading. 
 N.A. Epstein and L.P. FATTI38, in 1976 evaluated morphological 
features in 146 cases of prostatic carcinoma which were correlated with 5 
years survival, classifying it on the basis of Mc Neal's typing. They noted 
that if the tumour had indistinct cell borders and if there was no 
lymphocytic infiltration, then it was likely to have a very poor prognosis. 
 In 1976 Naomi A.Epstein39, studied positive aspiration smears of 34 
cases of histologically confirmed prostatic carcinoma. It was done to 
ascertain whether there was sufficient correlation between these features in 
aspiration smears and histological biopsies to enable prognosis to be 
assessed in cytological preparation. 
 He concluded that eventhough there was a 95% correlation in this 
study, the assessment of prognosis from morphological features was likely 
to be more accurate in sections than in smears, as the two features of 
prognostic significance-the presence or absence of cell borders and 
lymphocytic infiltration-can only be determined on sections. 
 In 1982, Alfred Bocking, et al40. formulated a new histological 
grading system for prostatic adenocarcinoma and tested its clinical 
significance. They concluded that survival probabilities of prostatic 
carcinoma patients were found to differ according to the actual least 
differentiated histological growth pattern. Survival time decreased with 
decreasing histological differentiation. 
 In 1986 Stacly E.Mills and Jackson E.Fowler41, compared the 
Gleason histological score of prostatic carcinoma in biopsy specimens to 
corresponding radical prostatectomy specimens from 53 patients with 
localized prostatic carcinoma. It was concluded that prostatic biopsy should 
be repeated when the initial diagnosis of adenocarcinoma is based on only 
limited quantities of neoplastic tissue with a low Gleason score and 
management decisions may be influenced by the true Gleason score. 
 There has been a little written about the diagnosis and reporting of 
adenocarcinoma of prostate diagnosed in core needle biopsy specimens. 
Jonathan I.Epstein42 in 1996 evaluated the importance of reporting prostatic 
carcinoma in trucut needle biopsy specimens in correlation with the radical 
prostatectomy specimens over 499 cases. He noted that 66% (328 of 499) 
of the trucut needle biopsy specimens remained in the same grading group 
as the radical prostatectomy specimens and he explained the practical 
difficulty in reporting prostatic adenocarcinoma in trucut needle biopsies. 
 Anand P.Chokkalingam, et al.43 in their study analyzed 86,626 men 
through a population based cohort study to assess the risk of prostatic 
carcinoma in 26 years, after the diagnosis of benign prostatic hyperplasia. 
They concluded that patients with BPH experienced excess risk of 
carcinoma (2% excess risk after 10 yrs. followup), when compared to 
general population. In contrast after first 5 years, patients with benign 
prostatic hyperplasia who did not receive surgical intervention had more 
risk compared to those who received treatment. 
Prognostic factors of prostatic adenocarcinoma  
1. Tumour related factors: 
• Anatomic extent of disease 
• Histologic grade 
• Polidy 
• Prostatic specific antigen (PSA) 
• Prostatic acid phosphatase (PAP) 
2. Patient related factors: 
• Age 
• Performance status-Pain, Obstructive symptoms 
• Serum creatinine 
3. Treatment related factors: 
• Previous TURP 
• Duration of primary response to hormone in progressive 
disease. 
 A number of studies have shown that prognostic factors for localized 
disease depends essentially on tumour related factors. Clinical staging and 
histological grading are amongst the most important and useful prognostic 
factors in prostatic cancer. 
MATERIALS AND METHODS 
 An analysis of 520 cases of surgically resected prostatic specimens 
referred from urology department from January 2004 to December 2005 for 
a two year period, has been carried out in Institute of Pathology, Madras 
Medical College, Chennai. 
 The histological material were derived from biopsy specimens of 
transurethral resection of prostate in 447 cases, trucut needle biopsy in 62 
cases and open prostatectomy in 11 cases. The age group of the patients 
ranged from 35-85 yrs. 
 Transurethral resection had been done to the patients who came to 
the urology out patient department with symptoms of urinary obstruction. If 
the patient had been clinically suspected of having carcinoma prostate by 
digital rectal examination, they were screened for prostatic specific antigen 
(PSA) level in the serum. Patients with elevated PSA levels in the serum or 
clinically suspicious patients or both have been selected for trucut needle 
biopsy. Only few patients underwent transrectal ultra sound (TRUS) guided 
biopsy. 
 As a routine, all prostatic specimens were fixed in 10% formalin. 
The total amount of prostatic chips received per each case varied grossly. 
But in general, we received 15 to 30 gm of prostatic chips for each case of 
TURP specimen. If the total amount of resected prostatic chips could be 
included in four histological sections it was examined in its entirety. Excess 
tissue was sampled at the rate of one histological section per 10 gram of 
resected tissue. 
 In most of the trucut biopsy specimens, we received only a bit of soft 
tissue measuring 0.5 to 1 cm and serial sections were taken from this. As a 
routine, 5 to 8 histological sections were taken from open prostatectomy 
specimens. 
 All these histological sections were stained with Haematoxylin & 
Eosin (H&E) stain and examined. In each benign prostatic hyperplasia and 
adenocarcinoma case diagnosed, the evaluation was done on the following 
variables, i.e. associated inflammatory aspects, presence of focal acinar 
atrophy, metaplastic lesions, hyperplastic lesions and premalignant lesions. 
All prostatic adenocarcinoma cases have been classified by the 
grading system of tumour differentiation described by Gleason et al. and 
thoroughly analysed for the presence of prostatic intra epithelial neoplasia 
(PIN) and atypical adenomatous hyperplasia (AAH). 
 
 
Procedure of haematoxylin and eosin stain: 
♦ Dewax the sections, hydrate through graded alcohols to water. 
♦ Remove fixation pigments if necessary. 
♦ Stain in haematoxylin for 5 minutes. 
♦ Wash well in running tap water until sections become `blue' for 5 
minutes. 
♦ Differentiate in 1 percent acid alcohol for 2-4 sec. 
♦ Wash well in running tap water until sections are again `blue' for 
15 to 20 minutes. 
♦ Stain in eosin for one minute. 
♦ Wash in tap water for 5 minutes. 
♦ Dry and mount the slide. 
 
RESULTS AND ANALYSIS 
 The histological spectrum of all associated epithelial and stromal 
lesions in benign prostatic hyperplasia and adenocarcinoma have been 
analyzed using various statistical tests. Out of 520 cases analyzed, 447 were 
TUPR specimens, 62 were trucut needle biopsies and 11 were open 
prostatectomy specimens. In total about 4619 cases of BPH and 41 cases of 
adenocarcinoma have been diagnosed in this two year period. 
Table: 1 
 
Distribution of cases in relation to surgical biopsy specimens 
 
Surgical biopsy specimens Total No. of 
cases 
Percent 
Transurethral resection of prostate 447 86% 
Trucut needle biopsy 62 12% 
Open prostatectomy 11 2% 
 
 
86%
12% 2%
TU R P Trucut O P
 
 
Table : 2 
 
Distribution of cases in relation to Age 
 
Age group No. of cases Percent 
31-40 Yrs 6 1.1% 
41-50 Yrs 31 5.9% 
51-60 Yrs. 127 26.3% 
61-70 Yrs. 214 41.5% 
70-80 Yrs. 118 22.6% 
81-90 Yrs 14 2.6% 
 
 
 
Table : 3 
 
Distribution of cases based on HPE diagnosis 
 
Lesions Total no. of 
cases 
TURP Trucut 
biopsy 
Open 
prostatectomy
BPH 461 (88.6%) 429 (96%) 21 (33.8%) 11 (100%) 
Adenocarcinoma 41 (7.8%) 18 (4%) 23 (37.2%) 0 
Inadequate tissue 18 (3.6%) 0 18 (29.0%) 0 
 
Table : 4 
 
EPITHELIAL CHANGES IN BENIGN PROSTATIC HYPERPLASIA 
 
S.No. Lesion No. of cases Percent 
1. Focal acinar/cystic atrophy 35 7.5% 
2. Squamous cell metaplasia 13 2.8% 
3. Transitional cell metaplasia 23 5.0% 
4. Mucinous metaplasia 1 0.2% 
5. Post atrophic hyperplasia 2 0.4% 
6. Basal cell hyperplasia 26 5.6% 
 Complete 14 3.0% 
 Incomplete 12 2.6% 
7. Clear cell cribriform hyperplasia 2 0.4% 
 
 
Table : 5 
 
STROMAL CHANGES IN BENIGN PROSTATIC HYPERPLASIA 
 
S.No. Lesion No. of cases Percent 
1. Chronic Inflammation 132 28.6% 
 Lymphocytic 125 27.1% 
 Granulomatous 7 1.5% 
2. Stromal nodule/hyperplasia 32 7.0% 
3. Stromal calcification 1 0.2% 
4. Leiomyomatous nodule 3 0.6% 
5. Infarction 3 0.6% 
6. Abscess 4 0.8% 
 
Putative premalignant lesions 
 Out of the putative premalignant lesions diagnosed in association 
with benign prostatic hyperplasia and prostatic adenocarcinoma, PIN 
changes constituted the major category. Among these, highgrade PIN was 
the most prevalent premalignant lesion diagnosed in cases of 
adenocarcinoma. Low grade PIN was more prevalent than high grade PIN 
in benign prostatic hyperplasia. 
 Atypical adenomatous hyperplasia was most commonly seen in cases 
diagnosed with benign prostatic hyperplasia. It was diagnosed only in one 
case of adenocarcinoma (see Table 6). Highgrade PIN changes were most 
commonly seen in trucut biopsy specimens in association with prostatic 
adenocarcinoma. Low grade PIN changes and atypical adenomatous 
hyperplasia were predominantly seen in TURP specimens (see table 7). 
 
Table : 6 
 
DISTRIBUTION OF PREMALIGNANT LESIONS IN RELATION TO 
HPE DIAGNOSIS 
 
Lesion AAH PIN Low grade 
PIN 
High grade 
PIN 
BPH 19 (4.1%) 90 (19.5%) 62 (13.4%) 28 (6.1%) 
Adenocarcinoma 1 (2.4%) 29 (70.7%) 8 (19.5%) 21 (51.2%) 
 
 
 
Table : 7 
 
PUTATATIVE PREMALIGNANT LESIONS IN RELATION TO 
BIOPSY SPECIMENS 
 
Lesions No. of cases TURP Trucut 
biopsy 
Open 
prostatectomy
AAH 20 (3.8%) 17 (3.8%) 2 (3.2%) 1 (9%) 
PIN Changes 119 (23%) 94 (21%) 23 (37%) 2 (18%) 
Low grade PIN 70 (13.5%) 59 (13.2%) 11 (17.7%) 0 
High grade PIN 49 (9.5%) 35 (7.8%) 12 (19.3%) 2 (18%) 
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Prostatic adenocarcinoma 
 Total number of adenocarcinoma cases diagnosed for a period of two 
years 41 cases. 
 
Table : 8 
 
DISTRIBUTION OF MALIGNANT CASES IN RELATION TO 
BIOPSY SPECIMENS 
 
Biopsy specimen No. of cases Percent 
TURP 18 44% 
Trucut 23 56% 
 
Table :9 
 
DISTRIBUTION OF ADENOCARCINOMA CASES BASED ON 
TUMOUR GRADING 
 
 
Grade No. of cases Percent 
I 10 24.3% 
II 12 29.3% 
III 14 34.2% 
IV 4 9.8% 
V 1 2.4% 
DISCUSSION 
 Benign prostatic hyperplasia and prostatic carcinoma, the two 
common urologic conditions among elderly men, share not only a similar 
hormonal milieu within the prostate, but also several epidemiologic and 
clinical factors. Both conditions increase with advancing age, both require 
androgens for growth and development and both respond to antiandrogenic 
therapy. Both share similar putative risk factors such as insulin-like growth 
factors, insulin and obesity. 
 Most of the patients, came with complaints of symptoms of urinary 
obstruction to the urology O.P. such as difficulty in micturition, hesitancy, 
frequency, pain during micturition and feeling of incomplete voiding. 
Patients suspected of having prostatic carcinoma on digital rectal 
examination were screened for prostatic specific antigen and if found to 
have elevated levels of prostatic specific antigen underwent trucut needle 
biopsy. Few patients were biopsied under the guidance of Transrectal ultra 
sound (TRUS). 
 Out of 520 cases analyzed in our study benign prostatic hyperplasia 
were found in 461 (88.6%) patients, prostatic adenocarcinoma in 41 (7.8%) 
patients and 18 (3.6%) trucut biopsy specimens turned out to be inadequate 
samples for making a diagnosis (See table-3). The patients were in the age 
group ranging from 35 to 85 yrs. The peak age group was 61 to 70 yrs, 
followed by 51-60 yrs (See table-2). 
Epithelial lesions 
 The total no. of 461 cases diagnosed with benign prostatic 
hyperplasia were analyzed for all other associated hyperplastic, metaplastic 
and atrophic lesions. Out of these lesions commonest were the focal acinar 
atrophy constituting 35 cases (7.5%) followed by basal cell hyperplasia in 
26 cases (5.6%) and transitional cell metaplasia in 23 cases (5.0%). Basal 
cell hyperplasia were classified into complete and incomplete forms with 
both the types showing almost equal incidence. Mucinous metaplasia and 
clear cell cribriform hyperplasia constituted less than 1% of cases but were 
of histomorphological interest. 
 Di Silverio F. et al.14 studied 3942 patients with benign prostatic 
hyperplasia and observed that focal acinar/cystic atrophy was found 
significantly increased according to the patient age in decades. In 
concurrence with the above study this study also showed 7.5% cases with 
cystic/acinar atrophy showing an increased incidence towards the higher 
age group. 
 Mahul B.Amin et al5. stated that the most commonly encountered 
pattern simulating the microacinar architecture of carcinoma is atrophy. A 
less common glandular pattern that forms part of the spectrum of atrophy is 
postatrophic hyperplasia, a lesion that has attained a renewed attention in 
the recent past in the literature. 
 Recently, several prostatic lesions composed of small glandular 
pattern mimicking adenocarcinoma have been identified or have had their 
diagnostic criteria refined. These include basal cell hyperplasia, sclerosing 
adenosis, atypical adenomatous hyperplasia (adenosis), post atrophic 
hyperplasia, hyperplasia of mesonephric duct remnants, verumontanum 
mucosal gland hyperplasia and nephrogenic adenoma of prostatic urethra 
secondarily involving prostatic parenchyma. 
 The small acinar pattern is commonly a source of consultation 
material, and approximately 5% to 10% of the cases in our study have had a 
preliminary diagnosis of carcinoma or a serious consideration of it. 
 So an awareness and firm understanding of the morphological 
spectrum of these epithelial lesions is of critical importance, especially in 
prostatic trucut needle biopsy specimens in which it shows some 
overlapping features with small acinar adenocarcinoma. And also the tissue 
sample obtained from the representative area is less and so the 
interpretation becomes difficult. 
 Many small acinar lesions of the prostate alluded to earlier have 
fairly consistent histological factors, and hence, there is little variation in 
their morphological expression. But post atrophic hyperplasia represents the 
process of hyperplasia and atrophy in transition and has less constant 
histology. The recognition of post atrophic hyperplasia in trucut needle 
biopsies is likely to be relatively straight forward, if the entire focus 
containing atrophic and hyperplastic glands is seen. Problems may arise 
when entire lesion is not represented. 
 Since basal cell hyperplasia has a distinctive microscopic 
appearance, its recognition is not difficult in most cases, but it may mimic 
adenocarcinoma of small acinar pattern, particularly if one is not familiar 
with this histological entity. BCH is characterized by a nodular growth of 
nests, tubules and cords filled with proliferating, small, darkly staining 
basal cells. Most of the nests of basal cell hyperplasia show vertical 
palisading of basal cells towards the periphery. 
 Young R.H. et al.6 study on prostatic lesions proved that basal cell 
hyperplasia is relatively a common lesion in hyperplastic prostates 
examined. This study also showed 26 cases (5.6%) and is more in number 
when compared to other hyperplastic and metaplastic lesions. 
 Squamous metaplasia of the prostatic glands was made out in 13 
(2.8%) cases and in three cases it was identified next to an area of infarct. 
Out of the 23 (5%) cases of transitional cell metaplasia most of the cases 
were found in the periurethral region/transitional zone, similar to the study 
done by Yantiss R.K. and Young, R.H8. 
 Clearcell cribriform hyperplasia is a rare entity made out only in two 
cases and it is important that CCCH should not be mistaken for a carcinoma 
or preneoplastic condition of the prostate with a papillary-cribriform 
pattern. The key to the diagnosis of CCCH is the combination of bland 
cytology and architectural uniformity. 
 In all these cases with small glandular proliferation basal cell layer is 
present. In problematic cases high molecular weight cytokeratin (Clone 34β 
E12) can be applied which will help accentuate the basal cells and confirm 
the benign diagnosis. 
 Frank et al.9 in their studies noted the alcianblue positivity in the 
luminal secretions of adenocarcinoma and they advocated this as a valuable 
aid to a make a diagnosis of well differentiated carcinoma. 
 Later studies done by David J.Grignon et al.11 have shown alcianblue 
positivity in acid mucin secretions in the lumina of basal cell hyperplasia, 
post atrophic hyperplasia, atrophy, sclerosing adenosis and in transitional 
cell metaplasia. So the acid mucin positivity can not be taken as a specific 
entity in making a diagnosis of carcinoma. 
 Hence it is stated that once a small acinar proliferation is identified, it 
need not be included in the final pathological diagnosis. However, it is 
recommended a mention should be made of this finding in the microscopic 
features, particularly if carcinoma is considered in the clinical/pathological 
evaluation. 
 More over these are not a distinct clinicopathological entities, but 
merely a pattern in the morphological spectrum which mimic cancer. So 
appreciation of key histological features is highly essential to make a 
reliable separation of small acinar carcinoma from there associated lesions 
which will reduce the diagnosis of `atypia' and `suspicious of carcinoma' in 
transurethral resection of prostate and especially in trucut needle biopsy 
specimens. 
Stromal lesions 
 All the cases diagnosed with benign prostatic hyperplasia were 
analyzed for stromal lesions. Proliferative stromal lesions were noticed in 
32 cases (7.0%). Chronic inflammation was the commonest lesion noticed 
in 132 cases (28.6%) out of which lymphocytic inflammatory infiltrate was 
seen in 125 cases ((27.1%) followed by granulomatous inflammation in 7 
cases only (1.5%). Stromal calcification was noticed in only one case 
(0.2%). Infarction and abscess constituted less than 1% of cases. 
 Di Silverio F. et al.14 study on 3942 patients with histopathological 
diagnosis of benign prostatic hyperplasia, the mean patient age was 68.85 ± 
7.67 yrs. In particular, inflammatory changes were associated with BPH in 
a high percentage of the cases (43.1%=1700 cases). In our study about 132 
cases having chronic inflammation were associated with BPH. 
 Out of 132 cases which showed inflammatory infiltrate the aspect of 
involvement with inflammatory reaction varied significantly according to 
prostate volume especially in case of lymphocytic infiltration. There was a 
trend to increase with increase in prostate volume. The inflammatory cells 
present in the tissue were primarily lymphocytes, monocytes, activated 
macrophages and mast cells. 
 Brian Difuccia et al.15 in his study demonstrated that the distribution 
of inflammation was more variable with multifocal and diffuse patterns 
being the most common and periglandular being less common. Multifocal 
inflammation was present in 48 to 68% of cases and diffuse inflammation 
was present in 24% of cases. Focal inflammation was only present in 4 to 
16% of cases. 
 Similar to the above study, evaluation of our cases showed 60 to 
80% with multifocal involvement of the tissue sample and 20 to 40% 
showed diffuse infiltration by chronic inflammatory cells. The severity of 
the inflammation also varied a lot. 
 A large variation in distribution of inflammation was found between 
microscopic fields of the same biopsy and also between different areas of 
the same blocks of prostatic tissue. One interesting case of tuberculous 
granulomatous prostatitis was also diagnosed in this study. 
 The evaluation of prostatic pathological findings with prostatitis has 
been problematic since they are only incidental findings in biopsies, which 
were performed for various other reasons. The diagnosis and treatment of 
prostatitis do not warrant surgical removal or biopsy of the prostate. Biopsy 
of these patients are rarely indicated or performed. 
 Stromal hyperplasia is most often seen in the setting of benign 
prostatic hyperplasia. It is characterized by bland spindle cell proliferation 
devoid of glandular elements. The distinction between stromal nodule and a 
leiomyoma is some what arbitrary. 
 Prostatic leiomyoma has not been universally accepted as a 
distinctive entity. Less than 70 cases of solitary leiomyoma has been 
reported in medical literature3. In this study three leiomyomatous nodules 
were diagnosed. Many other stromal lesions like phyllodes type tumour, 
blue nevus and fibroadenoma like lesion were not diagnosed in this study. 
Premalignant lesions 
 Since the introduction of prostate specific antigen (PSA), trucut 
needle biopsy has become one of the most common urological procedures. 
More than that, transrectal ultrasound directed biopsy permits the 
localization of the needle and the tissue being sampled. Often the only 
diagnosis rendered is that of highgrade prostate intra epithelial neoplasia 
(HGPIN) or atypical adenomatous hyperplasia (AAH)/atypical small acinar 
proliferation (ASAP). 
 PIN and AAH are considered as a putative premalignant lesions of 
adenocarcinoma. Prostatic intraepithelial neoplasia is defined as 
architecturally benign ducts and acini lined by abnormal secretory cells 
with changes similar to those in cancer. Atypical adenomatous hyperplasia 
denotes the presence of suspicious glands with insufficient cytological or 
architectural atypia for a definitive cancer diagnosis. 
 The morphological continuum of PIN that results in early invasive 
adenocarcinoma is now divided into two grades, low grade and high grade 
replacing the previous three grade system. PIN 1 is considered as low grade 
and PIN 2 and 3 are considered as high grade. 
Diagnostic criteria of PIN 
 Features Lowgrade PIN High Grade PIN 
A. Architectural 
features 
Epithelial cell 
crowding with 
irregular spacing 
Similar to low grade, more 
crowding & stratification 
B. Cytological features 
 • Nuclei Enlarged with 
considerable size 
variation 
Enlarged with some size and 
shape variation. 
 • Chromatin Normal Increase in density and  
clumping 
 • Nucleoli Rarely prominent Large and prominent, 
sometimes multiple 
C. Associated features 
 • Basal cell layer Intact May show disruption 
 • Basement     
membrane 
Intact Intact 
 
 McNeal & Bostwick17 study of 100 specimens of prostatic 
adenocarcinoma and 100 benign prostates obtained at autopsy, identified 
PIN in 82 prostates with carcinoma and 43 prostates without carcinoma. 
 Troncoso et al.19 studied sections from 100 prostate glands obtained 
from patients undergoing cystoprostatectomy for bladder carcinoma. He 
found PIN in 89 cases out of 100 prostates. Most of the PIN were 
multifocal and high grade. 
 Similar to the above studies, this study showed low grade PIN in 62 
cases (13.4%) of benign prostatic hyperplasia and in 8 cases (19.5%) of 
adenocarcinoma. High grade PIN were identified in 28 cases (6.1%) of 
benign prostatic hyperplasia and 21 (51.2%) cases of adenocarcinoma. This 
study also showed a high incidence of high grade PIN in cases of prostatic 
adenocarcinoma. 
 This fact has been emphasized by Junqi Qian, M.D. et al.23 study of 
195 radical prostatectomy specimens with clinically localized cancer. They 
identified PIN in 86% of prostates and it showed increased incidence of 
PIN with prostatic adenocarcinomas. 
 An overview of these studies show the clinical importance of 
recognizing PIN is actually based on its strong association with prostatic 
carcinoma. Prostatic intraepithelial neoplasia coexists with carcinoma in 
most cases. It retains an intact or fragmented basal cell layer unlike 
carcinoma which lacks basal cell layer. 
 Montironi & Schulman et al.20 have suggested that a small subset of 
basal cell layer houses the stem cell population. These cells are the 
presumptive origin of prostatic intraepithelial neoplasia and prostatic 
adenocarcinoma. 
 The histopathological continuum that culminates in high grade PIN 
and early invasive carcinoma is characterized by progressive basal cell 
layer disruption, changes in expression of markers of secretory 
differentiation, nuclear and nucleolar abnormalities, increasing microvessel 
density, cell proliferation, DNA content and allelic loss. 
 Virtually all phenotypic and genotypic studies of high grade PIN 
have indicated that it is more closely related to carcinoma than to benign 
epithelium. High grade PIN on its own has little or no significant influence 
on serum prostatic specific antigen concentration and does not cause 
clinically suspicious elevations. 
 Rekhi B. et al.27 studied 200 prostate specimens out of which 177 
cases of BPH, showed PIN changes in 53 (29.9%) cases and AAH in 38 
(20.3%) cases. All 6 cases (100%) of pure carcinoma revealed foci of PIN. 
 In this study out of 461 cases of benign prostatic hyperplasia, 
prostatic intraepithelial neoplastic (PIN) changes were identified in 90 cases 
(19.5%) and atypical adenomatous hyperplasia were identified in 19 cases 
(4.1%). Out of 41 cases of adenocarcinoma of prostate a total of 29 cases 
(70.7%) showed PIN changes. 
 Atypical adenomatous hyperplasia is a small acinar proliferation that 
is usually seen in intimate association with nodular hyperplasia in the 
transitional zone, often appearing at the periphery of a nodule. It shares 
many of the cytological features of the adjacent larger benign acini and is 
separated from well differentiated carcinoma by the presence of 
inconspicuous nucleoli infrequent crystalloid and a fragmented basal cell 
layer. 
 Nucleolar size is invariably smaller in atypical adenomatous 
hyperplasia than adenocarcinoma. Despite the utility of these features, the 
absolute distinction between AAH and carcinoma is difficult in some cases. 
This may possibly be a transition between normal prostate epithelium and 
well differentiated adenocarcinoma usually seen in the transitional zone. 
 Kien T. Mai29 in his study of 533 and 449 prostate specimens studied 
before and after the introduction of PSA screening respectively suggested 
that atypical adenomatous hyperplasia may be related to a subset of 
carcinoma that arises in transitional zone in association with benign 
prostatic hyperplasia. 
 In this study only one case (2.4%) of adenocarcinoma diagnosed in 
trucut needle biopsy showed the presence of atypical adenomatous 
hyperplasia. Other 19 cases (4.1%) of AAH were found in benign prostatic 
hyperplasia showing the representation from transitional zone. 
 There are many histological mimics for PIN such as atypical basal 
cell hyperplasia, cribriform hyperplasia and metaplastic changes associated 
with radiation and infarction. Atypical adenomatous hyperplasia can be 
confused with simple lobular atrophy, post atrophic hyperplasia, sclerosing 
atrophy, basal cell hyperplasia and verumontanum mucosal gland 
hyperplasia. 
 From this study it has been shown that the frequency of PIN in 
prostates with cancer is significantly increased when compared with benign 
prostates. High grade PIN was identified in 21 (51.2%) cases of 
adenocarcinoma and 28 cases (6.1%) of benign prostatic hyperplasia. It 
corresponds with many studies conducted previously per literature. 
 The data linking atypical adenomatous hyperplasia and carcinoma 
are limited and inconclusive. If AAH is a precursor to a subset of prostatic 
carcinoma, that subset of prostate carcinoma is most likely to be a low 
grade carcinoma in the transitional zone. High grade PIN provides the 
highest risk ratio of all known predictive factors and the identification of 
PIN in biopsies predicts the presence of carcinoma in subsequent biopsies. 
The risk of adenocarcinoma in subsequent biopsies is 15 times greater in 
patients with high grade PIN. 
 This finding indicates the need for repeat biopsy and follow up when 
high grade PIN is identified in a biopsy, especially in patients with an 
elevated serum prostatic specific antigen concentration. Studies to date have 
not determined whether PIN remains stable, regresses or progresses, though 
there is an implication that it can progress. 
Prostatic adenocarcinoma 
 Prostatic adenocarcinoma is often a multicentric malignant process 
consisting of two rather distinct types of PCa with different origins: 
 1.  Non transitional zone prostatic carcinoma (Non-TZPCa) 
 2. Transitional zone prostatic carcinoma (TZPCa) 
 Non transitional zone prostatic carcinoma is a tumour that is 
accessible to digital rectal examination and trans rectal ultrasound and is 
associated with high grade carcinoma, PIN and a high incidence of tumoral 
invasion into the prostatic capsule, perineural spaces and seminal vesicles. 
 In contrast transitional zone prostatic carcinoma is characterized by a 
low grade acinar pattern of carcinoma that is rarely associated with capsular 
invasion and seminal vesicle involvement. It is most likely  to arise from 
prostatic epithelium often in association with atypical adenomatous 
hyperplasia (AAH). Furthermore, AAH is more commonly identified in the 
transitional zone where as PIN is more prevalent in peripheral zone. 
 Due to the respective locations of these two types of carcinoma, a 
large proportion of incidental adenocarcinomas identified in transurethral 
resection of prostate is of TZ carcinoma type. With the introduction of 
prostatic specific antigen as a screening test for prostatic carcinoma, the 
incidence of PCa has been increased. This phenomenon was due to the 
early detection of prostatic carcinoma from the existing pool of carcinoma 
and not due to a net increase in the number of new cases. 
 Histological classification of tumours discriminate neoplasms 
according to their different histogenetic derivations primarily and allow 
predictions about the biological behaviour of the tumors. Histologic grading 
systems subdivide tumours of the same histogenetic origin into groups with 
different degrees of malignancy and different prognosis. 
 The prognostic significance of a grading system should be accepted 
only if a good correlation of tumour grades with survival probabilities of 
the different groups of patients can be demonstrated. Thus the clinical 
relevance of a grading system is established by correlating individual 
tumour grades with the clinical course of the disease. 
 Basic conditions for achieving this goal are: 
 1. that each applied diagnostic criterion should correlate with 
tumour malignancy and prognosis. 
 2. that the subjective grading results should be sufficiently 
reproducible 
 3. that the grading results obtained from biopsies should be 
sufficiently representative of tumour as a whole. 
 Out of 40 different histological classifications published, 19 have 
been examined closely for the prognostic significance. The Gleason's 
histological grading system has been accepted world wide as a grading 
system for prostatic carcinoma. 
GLASON'S GRADING SYSTEM FOR PROSTATIC 
ADENOCARCINOMA 
Score Appearance of 
glands 
Size of glands Architecture 
of glands 
Peripheral 
borders 
Stromal 
invasion 
Cytoplasm
1 Simple, round, 
monotonously 
replicated 
Medium, 
regular 
Closely 
packed, 
rounded 
masses 
Circumscribed, 
pushing and 
expansile 
Minimal Similar to 
benign 
epithelium 
2. Simple, round, 
some 
variability in 
shape 
Medium, less 
regular 
Loosely 
packed, 
rounded 
masses 
Less 
circumscribed, 
early infiltration
Mild, with 
definite 
separation of 
glands by 
stroma 
Similar to 
benign 
epithelium 
3. Angular, with 
variation in 
shape papillary 
and cribriform 
Small to 
Medium, 
Irregular 
Variably 
packed 
Ragged 
infiltration 
Marked More 
basophilic 
than (1) and 
(2) 
4. Micro acinar 
papillary & 
cribriform 
Irregular Fused in 
Chains & 
Cords 
Ragged 
infiltration 
Marked Dark, may 
be clear 
(hypernephr
oid) 
5. Few (or) no 
glands 
comedonecrosi
s may be 
present 
 Fused in sheets 
and masses 
Ragged 
infiltration 
Marked Variable 
 
 Based on the above features, the predominant primary pattern and 
the secondary pattern seen are scored and are summed up to produce the 
total score. Hence, the possibilities of total scores range from 2 to 10. 
 ♦ Low grade carcinomas 
  Gleason's score of 6 or less than that 
 ♦ High grade carcinomas 
  Gleason's score of 7 more than that 
Gleason's score in variants of prostatic adenocarcinoma 
 The variants of prostatic carcinoma account for fewer than 10% of 
cases and rarely occur in pure form. 
 The variants are: 
 ♦ Ductal endometrioid carcinoma without necrosis-(Gleason 
score 3) with necrosis (Gleason score 5) 
 ♦ Small cell undifferentiated carcinoma (Gleason score 5). 
 ♦ Mucinous carcinoma (Gleason score 4) 
 ♦ Signet-ring cell carcinoma (Gleason score 5) 
 ♦ Sarcomatoid carcinoma (Gleason score 5) 
 ♦ Carcino sarcoma (Gleason pattern 5) 
 ♦ Adenoid basal cell tumour (Gleason score 3 to 5). 
 ♦ Lymphoepithelioma like carcinoma (Gleason score 5). 
 ♦ Adenocarcinoma after androgen deprivation therapy (Gleason 
score 4 & 5). 
 Over the years, the grading system has stood the test of time and 
numerous studies have shown it to correlate strongly with survival rates, 
lymphnode metastasis, tumour volume, clinical stage and pathological 
stage. 
 Moreover Gleason's histological grading system is simple, easier to 
use and is confirmed by Stacey E.Millis, et al.41 and Jonathan I.Epstein, et 
al.42 and by many investigators as satisfactorily reproducible. 
 In this study, Gleason's grading system is applied over 41 cases of 
prostatic adenocarcinoma, diagnosed in these two year period of 2004 
and 2005. Out of which Grade III tumurs were the commonest  noticed in 
14 cases (34.2%) followed by Grade II in 12 cases (29.3%) and Grade I in 
10 cases (24.3%). 
 In this study out of 41 cases of adenocarcinoma reported more 
number (23 cases 56%) of malignant cases have been reported from 
trucut needle biopsy. Out of 62 trucut needle biopsies studied, 23 cases 
(37.2%) were diagnosed with adenocarcinoma, 21 cases (33.8%) with 
benign prostatic hyperplasia and 18 (29%) biopsy samples turned out to 
be inadequate or unsatisfactory. The last group of samples contained only 
few glands, fibrous tissue and/or blood clot only. 
 The diagnostic accuracy of prostatic adenocarcinoma in trucut 
needle biopsy is hampered by the less quantity of material available and 
numerous benign lesions that mimic adenocarcinoma histologically. 
 At times the limited biopsy material may lead to underestimation 
of Gleason's score and there by depriving the patients from getting the 
correct treatment. 
 In prostatic biopsy specimens, pathologists are not only called 
upon to diagnose carcinoma but also to quantify and grade these cancers 
accurately. This is to provide better prognostic information to the patients 
and also to inform the clinicians as to whether the tumour can be 
followed expectfully, treated definitively or to be treated palliatively 
because of its advanced clinical stage. 
SUMMARY AND CONCLUSION 
 Among all the surgical specimens received for the study period of 
two years in the Institute of pathology, the most common were 
TURP specimens with benign prostatic hyperplasia (92.1%) 
constituting the commonest histological category. Adenoarcinomas 
were found in 7.9% of cases. Most of the adenocarcinomas were 
diagnosed in trucut needle biopsy (56%).  
 About more than 90% of prostatic lesions studied were found in 
sixth to eighth decade. 
 All cases of focal acinar/cystic atrophy showed increase in trend 
towards increasing age in decades. 
 Among the hyperplastic lesions, basal cell hyperplasia was found 
to be the most common epithelial lesion (26 cases) compared to the 
other lesions such as postatrophic hyperplasia, clear cell cribriform 
hyperplasia etc. 
 Transitional cell metaplasia was found to be the most common 
metaplastic lesion (23 cases) and about half of the cases were 
found in association with chronic prostatitis. About one fourth of 
the cases of squamous cell metaplasia were found in the periphery 
of areas of an infarct. 
 Chronic inflammation was the most common stromal lesion 
noticed in 145 cases (27.8%) predominantly it is a lymphocytic 
inflammatory infiltrate with multifocal and diffuse distribution 
seen in association with benign prostatic hyperplasia in 28.6% 
cases and with adenocarcinoma in 31.7% cases. One interesting 
case of tuberculous granulomatous prostatitis was also diagnosed. 
 Among the premalignant lesions, PIN changes (70.7%) were found 
most commonly in association with prostatic adenocarcinoma. Out 
of which high grade PIN (51.2%) was the commonest premalignant 
lesion observed. 
 Though atypical adenomatous hyperplasia is considered to be a 
putative premalignant lesion, contrarily it was observed only in one 
case (2.4%) of prostatic adenocarcinoma. Most commonly it was 
observed in 19 cases (4.1%) of benign prostatic hyperplasia. 
 In concurrence with the literature it was observed that high grade 
PIN was the most common premalignant lesions associated with 
prostatic adenocarcinoma (51.2%) rather than atypical 
adenomatous hyperplasia. AAH was mostly observed in 
transitional zone and is probably a precursor of low grade 
adenocarcinomas arising in transitional zone. 
 MASTER CHART 
 
o. Biopsy No. Age/Male Biopsy Specimen Histopathological Diagnosis Associated Lesions 
85/04 70 TURP BPH  
86/04 58 TURP BPH Cystic atrophy, chronic prostatitis 
o. Biopsy No. Age/Male Biopsy Specimen Histopathological Diagnosis Associated Lesions 
87/04 39 TURP BPH Chronic prostatitis, squamous metaplasia, transitional cell
152/04 51 TURP BPH Stromal nodule 
160/04 55 TURP BPH Chronic prostatitis 
162/04 62 TURP BPH Cystic Atrophy 
202/04 75 TURP BPH Cystic Atrophy 
291/04 70 TURP BPH  
293/04 67 TURP BPH Squamous metaplasia, mucinous metaplasia 
345/04 65 TURP BPH Transitional cell metaplasia 
346/04 65 TURP BPH Chronic prostatitis 
351/04 50 TURP BPH Chronic prostatitis 
609/04 69 Trucut BPH  
621/04 60 TURP BPH  
692/04 55 TURP Adenocarcinoma Grade III High Grade PIN 
716/04 60 TURP BPH Cystic atrophy, transitional cell metaplasia 
717/04 73 TURP BPH High grade PIN 
719/04 70 Trucut Inadequate tissue  
736/04 80 TURP BPH  
821/04 60 Trucut Adenocarcinoma Grade II Low grade PIN 
822/04 55 Trucut BPH  
831/04 61 TURP BPH Cystic atrophy 
881/04 74 TURP BPH Chronic prostatitis 
882/04 75 TURP Adenocarcinoma Grade III High grade PIN 
936/04 70 TURP BPH Chronic prostatitiss 
951/04 60 Trucut Adenocarcinoma Grade IV High grade PIN 
973/04 55 TURP BPH Stromal nodule 
974/04 50 TURP BPH Chronic prostatitis 
996/04 65 TURP BPH  
1092/04 60 Trucut Tiny Tissue  
1097/04 70 Trucut Only fibrous tissue  
1105/04 62 TURP BPH Chronic prostatitis 
1107/04 68 TURP BPH Basalcell hyperplasia-complete, transitional cell metaplas
1149/04 65 TURP BPH Low grade PIN 
1156/04 73 Trucut Adenocarcinoma Grade II  
1192/04 60 Trucut Adenocarcinoma Grade III High grade PIN 
1193/04 69 TURP BPH Leiomyomatous nodule 
1247/04 67 TURP BPH Chronic prostatitis 
1248/04 63 TURP Adenocarcinoma Grade II Low grade PIN 
1249/04 65 TURP BPH Chronic prostatitis 
1274/04 66 TURP Adenocarcinoma Grade III Chronic prostatitis 
1288/04 52 TURP BPH  
o. Biopsy No. Age/Male Biopsy Specimen Histopathological Diagnosis Associated Lesions 
1335/04 73 TURP BPH  
1418/04 72 Trucut Adenocarcinoma Grade III High grade PIN 
1435/04 60 Trucut Adenocarcinoma Grade II  
1441/04 65 TURP BPH Chronic prostatitis 
1442/04 55 TURP BPH Low grade PIN, Chronic prostatitis 
1464/04 72 TURP BPH High grade PIN 
1552/04 48 TURP BPH Stromal hyperplasia, Leiomyomatous nodule 
1567/04 87 Trucut BPH Low grade PIN 
1590/04 65 TURP BPH Low grade PIN 
1630/04 80 TURP BPH Transitional cell metaplasia 
1631/04 60 TURP BPH Chronic prostatitis 
1632/04 80 TURP BPH Chronic prostatitis 
1654/04 50 TURP BPH Cystic atrophy 
1656/04 53 TURP BPH  
1773/04 77 TURP BPH Cystic atrophy 
1825/04 70 TURP BPH Chronic prostatitis 
1840/04 70 TURP BPH Transitional cell metaplasia 
1867/04 64 Trucut Adenocarcinoma Grade II  
1871/04 49 TURP BPH  
1892/04 72 TURP BPH Low grade PIN 
1893/04 65 TURP BPH Chronic prostatitis, Abscess 
1996/04 60 TURP BPH Corpora amylacea 
2008/04 64 TURP BPH Cystic atrophy 
2009/04 73 TURP BPH Chronic prostatitis, Atypical adenomatous hyperplasia 
2044/04 52 TURP BPH Chronic prostatitis 
2045/04 54 TURP BPH  
2168/04 68 TURP BPH Low grade PIN 
2206/04 55 Trucut BPH Squamous metaplasia 
2272/04 70 Trucut Inadequate tissue  
2316/04 78 TURP BPH Low grade PIN, chronic prostatitis 
2317/04 50 TURP BPH Low grade PIN 
2335/04 71 Trucut Adenocarcinoma grade III Chronic prostatitis 
2337/04 70 TURP BPH Chronic prostatitis 
2392/04 71 TURP BPH Low grade PIN, Clearcell cribriform hyperplasia 
2393/04 75 TURP BPH Chronic prostatitis 
2468/04 55 TURP BPH  
2470/04 51 TURP BPH Low grade PIN, chronic prostatitis 
2499/04 60 TURP BPH Stromal nodule, lymphocytic prostatitis 
2506/04 73 TURP BPH Chronic prostatitis 
2534/04 54 TURP BPH Squamous metaplasia, Chronic prostatitis, Infarction 
o. Biopsy No. Age/Male Biopsy Specimen Histopathological Diagnosis Associated Lesions 
2537/04 66 TURP BPH  
2538/04 75 Open Prostatectomy BPH Cystic atrophy, chronic prostatitis 
2542/04 65 Trucut BPH  
2570/04 56 TURP BPH Chronic prostatitis 
2571/04 66 TURP BPH Stromal nodule 
2601/04 80 TURP BPH Low grade PIN 
2603/04 50 TURP BPH Stromal hyperplasia 
2604/04 52 TURP BPH Lymphocytic prostatitis 
2699/04 60 TURP BPH Low grade PIN, Basalcell hyperplasia-Incomplete 
2727/04 73 TURP BPH Low grade PIN 
2739/04 75 Open Prostatectomy BPH Atypical adenomatous hyperplasia 
2740/04 60 TURP BPH Cystic atrophy, lyumphocytic prostatitis 
2762/04 60 TURP BPH Basalcell hyperplasia-complete, Lowgrade PIN 
2764/04 62 TURP BPH Lymphocytic prostatitis 
2805/04 75 Trucut BPH  
2870/04 70 TURP BPH Transitional cell metaplasia 
2891/04 75 TURP BPH Basalcell hyperplasia-Incomplete, Lowgrade PIN 
. 2893/04 70 TURP BPH Chronic prostatitis 
. 2894/04 70 TURP BPH  
. 2925/04 60 TURP BPH High grade PIN 
. 2962/04 55 TURP BPH Infarction, squamous metaplasia, cystic atrophy 
. 2964/04 60 TURP BPH Transitional cell metaplasia 
. 3001/04 70 TURP BPH Stromal nodule, lymphocytic prostatitis 
. 3004/04 62 TURP BPH  
. 3032/04 72 TURP BPH Lymphocytic prostatitis 
. 3074/04 58 TURP BPH Chronic prostatitis 
. 3082/04 55 TURP BPH Low grade PIN 
. 3099/04 64 Trucut BPH High grade PIN 
. 3107/04 60 TURP BPH Stromal nodule, Low grade PIN 
. 3162/04 50 TURP BPH  
. 3182/04 50 Open Prostatectomy BPH Cystic atrophy 
. 3183/04 69 TURP BPH  
. 3206/04 60 TURP BPH High grade PIN, transitional cell metaplasia 
. 3225/04 50 TURP BPH High grade PIN 
. 3253/04 65 TURP BPH Chronic prostatitis 
. 3254/04 65 TURP BPH  
. 3255/04 67 TURP BPH Basalcell hyperplasia-complete 
. 3268/04 65/M Trucut Only fibrocollagenous tissue  
. 3303/04 70 TURP BPH High grade PIN 
. 3304/04 40 TURP BPH High grade PIN  
o. Biopsy No. Age/Male Biopsy Specimen Histopathological Diagnosis Associated Lesions 
. 3305/04 70 TURP BPH  
. 3327/04 68 TURP BPH Low grade PIN, chronic prostatitis 
. 3340/04 65 TURP BPH Stromal nodule 
. 3341/04 70 TURP BPH Chronic lymphocytic prostatitis 
. 3347/04 69 Trucut BPH  
. 3370/04 55 TURP BPH Corpora amylacea, stromal calcification 
. 3380/04 70 TURP BPH Chronic prostatitis, cystic atrophy 
. 3407/04 60 TURP BPH Granulomatous prostatitis 
. 3484/04 75 TURP BPH  
. 3503/04 73 TURP BPH Focal basal cell hyperplasia-complete 
. 3524/04 65 TURP BPH  
. 3525/04 65 TURP BPH Basal cell hyperplasia-Incomplete 
. 3526/04 62 TURP BPH  
. 3605/04 55 TURP BPH Transitional cell metaplasia 
. 3616/04 70 TURP BPH Atypical adenomatous hyperplasia 
. 3617/04 63 TURP BPH Low grade PIN 
. 3634/04 75 TURP Adenocarcinoma Grade I Chronic prostatitis 
. 3657/04 69 TURP BPH Chronic prostatitis 
. 3692/04 73 TURP BPH Low grade PIN 
. 3693/04 62 TURP BPH  
. 3694/04 75 TURP BPH  
. 3773/04 70 TURP BPH Stromal hyperplasia  
. 3775/04 65 TURP BPH Chronic prostatitis 
. 3776/04 70 TURP BPH Atypical adenomatous hyperplasia 
. 3783/04 72 TURP BPH Stromal hyperplasia  
. 3815/04 75 TURP BPH  
. 3840/04 60 TURP BPH Lymphocytic prostatitis 
. 3841/04 60 TURP BPH Low grade PIN 
. 3931/04 78 TURP BPH Low grade PIN 
. 4334A/04 55 TURP BPH  
. 4374/04 70 TURP BPH Lymphocytic prostatitis 
. 4419/04 64 TURP BPH  
. 4420/04 70 TURP BPH Stromal nodule 
. 4421/04 65 TURP BPH  
. 4479/04 53 Trucut Adenocarcioma Grade I Low grade PIN 
. 4530/04 72 TURP Adenocarcioma Grade II High grade PIN 
. 4545/04 75 TURP BPH Chronic prostatitis 
. 4563/04 62 TURP BPH  
. 4568/04 70 TURP BPH Atypical adenomatous hyperplasia 
. 4597/04 50 TURP BPH Transitional cell metaplasia 
o. Biopsy No. Age/Male Biopsy Specimen Histopathological Diagnosis Associated Lesions 
. 4629/04 60 TURP BPH Chronic prostatitis 
. 4630/04 65 Trucut Adenocarcinoma Grade-II  
. 4631/04 69 TURP BPH  
. 4633/04 60 TURP BPH  
. 4708/04 65 Trucut BPH Low grade PIN, Postatrophic hyperplasia 
. 4717/04 65 TURP BPH Basal cell hyperplasia-complete 
. 4718/04 64 TURP BPH Low grade PIN 
. 4834/04 70 Trucut Only blood clot  
. 4890/04 68 TURP BPH Chronic prostatitis 
. 4938/04 68 TURP BPH Granulomatous prostatitis, Atypical adenomatous hyperpl
. 4941/04 60 TURP BPH  
. 5020/04 72 TURP BPH  
. 5023/04 65 TURP BPH Low grade PIN 
. 5048/04 65 Trucut Adenocarcinoma Grade-I High grade PIN 
. 5184/04 52 TURP Adenocarcinoma Grade-II High grade PIN 
. 5185/04 65 TURP BPH Chronic prostatitis 
. 5206/04 55 TURP BPH Atypical adenomatous hyperplasia 
. 5208/04 56 TURP BPH Basalcell hyperplasia-Incomplete 
. 5280/04 65 TURP BPH Corpora amylacea 
. 5307/04 61 TURP BPH  
. 5392/04 75 TURP BPH Chronic prostatitis, Abscess 
. 5461/04 71 TURP BPH Transitional cell metaplasia 
. 5484/04 53 TURP BPH Chronic lymphocytic prostatitis 
. 5489/04 70 TURP BPH High grade PIN 
. 5490/04 72 Trucut Adenoocarcinoma Grade-I High grade PIN 
. 5518/04 50 TURP BPH Chronic prostatitis 
. 5519/04 75 TURP BPH  
. 5520/04 65 Open Prostatectomy BPH Cystic atrophy 
. 5527/04 67 TURP BPH Stromal hyperplasia 
. 5549/04 60 TURP BPH  
. 5550/04 06 TURP BPH High grade PIN 
. 5632/04 70 TURP BPH Chronic prostatitis 
. 5650/04 60 TURP BPH Atypical adenomatous hyperplasia 
. 5657/04 70 Open prostatectomy BPH Corpora amylacea 
. 5686/04 65 TURP BPH Chronic prostatitis, Low grade PIN 
. 5712/04 61 TURP BPH  
. 5713/04 50 TURP BPH  
. 5760/04 75 TURP BPH Chronic prostatitis 
. 5780/04 78 TURP BPH Chronic prostatitis 
. 5786/04 68 TURP BPH Low grade PIN 
o. Biopsy No. Age/Male Biopsy Specimen Histopathological Diagnosis Associated Lesions 
. 5809/04 60 TURP BPH  
. 5829/04 70 TURP BPH Atypical adenomatous hyperplasia 
. 5830/04 60 TURP BPH High grade PIN 
. 5854/04 57 Trucut Adenocarcinoma Grade-II High grade PIN  
. 5861/04 73 TURP BPH Chronic prostatits 
. 5862/04 60 TURP BPH Atypical adenomatous hyperplasia 
. 5906/04 68 TURP BPH Squamous metaplasia, Infarction 
. 5907/04 85 TURP BPH  
. 5941/04 64 TURP BPH Chronic prostatitis 
. 5943/04 66 TURP BPH Corpora amylacea 
. 5978/04 60 TURP BPH Chronic prostatitis 
. 5979/04 41 TURP BPH Acinar atrophy 
. 5981/04 82 Open Prostatectomy BPH Corpora amylacea, cysticatrophy 
. 6056/04 64 TURP BPH  
. 6057/04 75 TURP BPH Stromal nodule, Low Grade PIN 
. 6074/04 74 Trucut Adenocarcinoma Grade-I Low grade PIN, Chronic prostatitis 
. 6076/04 60 TURP BPH  
. 6077/04 67 TURP BPH  
. 6078/04 75 Open prostatectomy BPH Chronic prostatitis 
. 6129/04 71 TURP BPH Transitional cell metaplasia, stromal nodule 
. 6138/04 77 TURP BPH Low grade PIN 
. 6153/04 62 TURP BPH  
. 6220/04 70 Trucut Only blood clot  
. 6223/04 82 TURP BPH Corpora amylacea 
. 6225/04 50 Open prostatectomy BPH High grade PIN, stromal nodule 
. 6226/04 48 TURP BPH  
. 6273/04 65 TURP BPH Chronic prostatitis 
. 6301/04 72 TURP Adenocarcinoma Grade-I High grade PIN 
. 6302/04 70 TURP BPH Low grade PIN 
. 6367/04 65 TURP BPH Chronic prostatitis, Atypical adenomatous hyperplasia 
. 6422/04 54 TURP BPH  
. 6423/04 74 TURP BPH Transitional cell metaplasia, lymphocytic prostatitis 
. 6487/04 70 TURP BPH  
. 6491/04 76 TURP BPH  
. 6492/04 65 TURP BPH Stromal nodule 
. 6586/04 65 TURP BPH Atypical adenomatous hyperplasia 
. 6632/04 75 TURP BPH Granulomatous prostatitis 
. 6635/04 60 TURP BPH High grade PIN 
. 6675/04 70 TURP BPH Chronic prostatitis 
. 6676/04 60 TURP BPH Low grade PIN 
o. Biopsy No. Age/Male Biopsy Specimen Histopathological Diagnosis Associated Lesions 
. 6694/04 70 Open Prostatectomy BPH Cystic atrophy 
. 6740/04 53 TURP BPH  
. 6742/04 67 TURP BPH Basalcell hyperplasia-Complete 
. 6744/04 70 TURP BPH Stromal nodule 
. 6767/04 68 TURP BPH Chronic prostatitis 
. 6768/04 82 TURP BPH Chronic prostatitis 
. 6861/04 75 TURP BPH Bacterial prostatitis, Abscess, High grade PIN 
. 6862/04 60 TURP BPH Granulomatous prostatitis 
. 6903/04 71 TURP BPH Squamous metaplasia, Transitionalcell metaplasia, High g
. 6906/04 63 TURP BPH  
. 6987/04 55 Trucut Inadequate tissue  
. 6989/04 65 TURP BPH Chronic prostatitis 
. 6990/04 65 TURP BPH Low grade PIN 
. 7032/04 70 TURP BPH Cystic atrophy 
. 7033/04 69 TURP BPH Lymphocytic prostatitis 
. 7048/04 60 TURP BPH Atypical adenomatous hyperplasia 
. 7127/04 72 TURP BPH  
. 7161/04 60 TURP BPH Basal cell hyperplasia-Incomplete 
. 7162/04 72 TURP Adenocarcinoma Grade III High grade PIN, Chronic prostatitis 
. 7202/04 62 TURP BPH  
. 7203/04 70 TURP BPH Leiomyomatous nodule 
. 7219/04 55 TURP BPH Chronic prostatitis 
. 7280/04 51 TURP BPH  
. 7281/04 65 TURP BPH Stromal nodule 
. 7345/04 70 TURP BPH Atypical adenomatous hyperplasia 
. 7416/04 65 TURP BPH  
. 7417/04 71 TURP BPH  
. 7430/04 75 TURP BPH Low grade PIN 
. 7431/04 53 TURP BPH  
. 7451/04 60 TURP BPH Chronic prostatitis 
. 7452/04 65 TURP BPH Infarction, squamous metaplasia, Lymphocytic prostatitis
. 7476/04 67 TURP BPH Chronic prostatitis 
. 7480/04 50 TURP BPH  
. 7481/04 71 TURP BPH Low grade PIN 
. 9485/04 62 TURP BPH  
. 12/05 76 TURP BPH Stromal nodule 
. 220/05 67 TURP BPH  
. 255/05 70 TURP BPH Chronic prostatitis, cystic atrophy 
. 256/05 70 TURP BPH Transitional cell metaplasia 
. 257/05 74 TURP BPH Chronic prostatitis 
o. Biopsy No. Age/Male Biopsy Specimen Histopathological Diagnosis Associated Lesions 
. 311/05 59 TURP BPH High grade PIN 
. 313/05 73 TURP BPH  
. 317/05 63 Trucut BPH Atypical adenomatous hyperplasia 
. 348/05 70 TURP BPH Low grade PIN, Cystic atrophy 
. 360/05 60 TURP BPH Transitional cell metaplasia 
. 361/05 55 Trucut Adenocarcinoma Grade III  
. 413/05 66 TURP BPH Chronic prostatitis 
. 415/05 56 TURP BPH Chronic prostatitis, Low grade PIN 
. 439/05 61 TURP BPH  
. 440/05 35 TURP BPH Basalcell hyperplasia-Incomplete  
. 443/05 60 Trucut BPH Chronic prostatitis 
. 483/05 40 TURP BPH Atypical adenomatous hyperplasia 
. 485/05 51 TURP BPH  
. 547/05 55 TURP BPH Chronic lymphocytic prostatitis 
. 588/05 77 Trucut Only haemorrhage  
. 589/05 60 Trucut Only bladder mucosa  
. 594/05 55 TURP BPH Low grade PIN 
. 595/05 60 TURP BPH Chronic prostatitis 
. 623/05 80 TURP BPH Basalcell hyperplasia-complete  
. 624/05 72 TURP BPH Squamous metaplasia, Infarction 
. 666/05 58 TURP BPH Low grade PIN 
. 671/05 60 TURP BPH Chronic prostatitis 
. 681/05 75 Trucut Inadequate tissue  
. 722/05 70 TURP BPH High grade PIN 
. 723/05 52 TURP BPH Acinar atrophy, stromal nodule 
. 727/05 70 TURP BPH  
. 787/05 47 Trucut BPH Chronic prostatitis 
. 788/05 55 TURP BPH  
. 815/05 71 TURP BPH Low grade PIN 
. 858/05 65 Trucut Adenocarcinoma Grade-II High grade PIN, Lymphocytic prostatitis 
. 859/05 75 Trucut Few prostatic glands  
. 866/05 66 TURP BPH Cystic atrophy 
. 927/05 77 Trucut Adenocarcinoma Grade-I Chronic prostatitis 
. 959/05 70 TURP BPH Basalcell hyperplasia-Incomplete  
. 1011/05 75 TURP BPH Chronic prostatitis 
. 1013/05 61 TURP BPH Low grade PIN 
. 1036/05 56 TURP BPH  
. 1037/05 65 TURP BPH Corpora amylacea 
. 1067/95 76 TURP BPH Tuberculous granulomatous prostatitis 
. 1127/05 42 Trucut BPH  
o. Biopsy No. Age/Male Biopsy Specimen Histopathological Diagnosis Associated Lesions 
. 1129/05 71 TURP BPH Low grade PIN 
. 1153/05 70 TURP BPH Transitional cell metaplasia, squamous metaplasia 
. 1193/05 70 TURP BPH Basal cell hyperplasia-complete 
. 1194/05 65 TURP BPH  
. 1304/05 77 TURP BPH Cystic atrophy 
. 1305/05 60 TURP BPH Chronic prostatitis 
. 1337/05 75 TURP BPH High grade PIN 
. 1338/05 55 TURP Adenocarcinoma Grade-II Low grade PIN 
. 1369/05 65 TURP BPH  
. 1370/05 60 TURP BPH Stromal hyperplasia 
. 1430/05 70 TURP BPH  
. 1486/05 84 TURP BPH Low grade PIN 
. 1490B/05 68 TURP BPH  
. 1602A/05 70 TURP BPH  
. 1603/05 60 TURP Adenocarcinoma Grade-IV Chronic prostatitis, High grade PIN 
. 1672/05 50 TURP BPH Low grade PIN 
. 1675/05 75 TURP BPH Chronic prostatitis 
. 1696/05 62 Open Prostatectomy BPH Cystic atrophy 
. 1697/05 59 TURP BPH Basalcell hyperplasia-Incomplete 
. 1698/05 62 TURP BPH  
. 1743/05 63 TURP BPH Chronic prostatitis 
. 1814/05 70 TURP BPH Basalcell hyperplasia-complete 
. 1818/05 55 TURP BPH  
. 1859/05 76 Trucut BPH Atypical adenomatous hyperplasia 
. 1886/05 68 TURP BPH  
. 1887/05 80 TURP BPH Basalcell hyperplasia-Incomplete 
. 1922/05 52 Trucut BPH Prostatitis, Low grade PIN 
. 1946/05 67 TURP BPH  
. 1948/05 61 TURP BPH Chronic prostatitis 
. 1949/05 60 TURP BPH Chronic prostatitis 
. 1993/05 70 Turcut Adenocarcinoma Grade-II High grade PIN 
. 2037/05 65 TURP BPH Cystic atrophy 
. 2068/05 72 Trucut BPH  
. 2083/05 60 TURP BPH Transitional cell metaplaisa 
. 2100/05 74 TURP BPH  
. 2156/05 80 TURP BPH Stromal hyperplasia 
. 2176/05 55 TURP BPH  
. 2204/05 51 TURP BPH Atypical adenomatous hyperplasia 
. 2263/05 65 TURP BPH Low grade PIN 
. 2276/05 60 TURP BPH Chronic prostatitis 
o. Biopsy No. Age/Male Biopsy Specimen Histopathological Diagnosis Associated Lesions 
. 2334/05 60 TURP BPH Cystic atrophy 
. 2335/05 70 TURP BPH Chronic prostatitis 
. 2356/05 54 TURP BPH Fungal prostatitis 
. 2357/05 70 TURP BPH  
. 2406/05 55 TURP BPH Stromal hyperplasia 
. 2492/05 60 TURP BPH Transitional cell metaplasia 
. 2493/05 67 TURP BPH Low grade PIN 
. 2495/05 61 TURP BPH Chronic prostatitis 
. 2517/05 65 TURP BPH Basalcell hyperplasia-complete 
. 2518/05 63 TURP BPH Chronic prostatitis 
. 2574/05 75 TURP BPH  
. 2634/05 74 Trucut BPH Low grade PIN, postatrophic hyperplasia 
. 2636/05 45 Trucut Only fibrous tissue  
. 2637/05 43 TURP BPH  
. 2638/05 69 TURP BPH Squamous metaplasia, Infarction 
. 2718/05 75 TURP BPH Low grade PIN 
. 2740/05 75 TURP BPH Chronic prostatitis 
. 2742/05 73 TURP BPH  
. 2783/05 53 TURP BPH Chronic prostatitis 
. 2807/05 55 TURP BPH  
. 2861/05 75 TURP BPH High grade PIN 
. 2881/05 75 TURP BPH  
. 2882/05 77 TURP BPH Low grade PIN 
. 2920/05 75 Trucut BPH Low grade PIN 
. 2925/05 55 TURP BPH Chronic prostatitis, Basalcell hyperplasia-Incomplete 
. 2926/05 66 TURP BPH Chronic prostatitis 
. 2942/05 75 TURP BPH  
. 2945/05 60 TURP BPH Cystic atrophy 
. 2947/05 32 TURP BPH  
. 3018/05 50 TURP Adenocarcinoma grade II Chronic prostatitis 
. 3058/05 62 TURP BPH Stromal nodule, Chronic prostatitis 
. 3125/05 65 TURP BPH Squamous metaplasia 
. 3128/05 80 TURP BPH Stromal hyperplasia 
. 3139/05 65 Trucut Only few prostatic glands  
. 3207/05 65 TURP BPH  
. 3234/05 72 TURP BPH Chronic prostatitis 
. 3351/05 65 TURP BPH  
. 3353/05 55 TURP BPH Basalcell hyperplasia-complete  
. 3385/05 75 TURP BPH Cystic atrophy 
. 3386/05 60 TURP BPH Chronic prostatitis 
o. Biopsy No. Age/Male Biopsy Specimen Histopathological Diagnosis Associated Lesions 
. 3411/05 72 TURP BPH Transitional cell metaplasia 
. 3413/05 51 TURP BPH  
. 3414/05 60 TURP BPH  
. 3470/05 72 TURP BPH Corpora amylacea 
. 3484/05 55 TURP BPH Chronic prostatitis 
. 3485/05 75 TURP BPH Corpora amylacea 
. 3563/05 67 TURP BPH High grade PIN, corpora amylacea 
. 3591/05 54 Trucut BPH Atypical adenomatous hyperplasia 
. 3616/05 65 TURP BPH Basalcell hyperplasia-complete  
. 3657/05 64 TURP BPH Chronic prostatitis 
. 3681/05 65 TURP BPH Low grade PIN 
. 3702/05 70 Open Prostatectomy BPH Atypical adenomatous hyperplasia 
. 3704/05 60 TURP BPH  
. 3705/05 60 TURP BPH Chronic prostatitis 
. 3746/05 64 Trucut Adenocarcinoma Grade III High grade PIN 
. 3755/05 75 Trucut Adenocarcinoma Grade III High grade PIN 
. 3757/05 85 TURP BPH Cystic atrophy 
. 3783/05 65 TURP BPH  
. 3784/05 55 TURP BPH Transitional cell metaplasia 
. 3857/05 70 TURP Adenocarcinoma grade II Chronic prostatitis, Low grade PIN 
. 3858/05 70 TURP BPH Chronic lymphocytic prostatitis 
. 3859/05 76 TURP BPH Corpora amylacea 
. 3913/05 40 TURP BPH Stromal hyperplasia 
. 3929/05 60 Trucut Adenocarcinoma grade V Chronic prostatitis 
. 3935/05 80 TURP BPH Low grade PIN 
. 3936/05 72 TURP Adenocarcinoma Grade I Chronic prostatitis 
. 3979/05 70 TURP BPH  
. 4011/05 72 TURP BPH Chronic prostatitis 
. 4012/05 86 TURP BPH  
. 4013/05 57 TURP BPH Stromal nodule 
. 4067/05 63 TURP BPH Chronic prostatitis 
. 4092/05 73 Trucut Only few prostatic glands  
. 4095/05 69 TURP BPH Low grade PIN 
. 4130/05 65 TURP BPH High grade PIN 
. 4163/05 52 TURP BPH  
. 4164/05 63 TURP BPH Chronic prostatitis 
. 4227/05 75 TURP BPH  
. 4239/05 70 TURP BPH Cystic atrophy 
. 4263/05 65 Trucut Adenocarcinoma Grade III Chronic prostatitis, Low grade PIN 
. 4283/05 65 TURP BPH Chronic prostatitis 
o. Biopsy No. Age/Male Biopsy Specimen Histopathological Diagnosis Associated Lesions 
. 4335/05 65 TURP BPH  
. 4361/05 54 TURP BPH Xantho granulomatous prostatitis 
. 4362/05 50 TURP BPH Corpora amylacea 
. 4488/05 68 TURP BPH Chronic prostatitis 
. 4543/05 50 TURP BPH Chronic prostatitis 
. 4700/05 60 TURP BPH Low grade PIN 
. 4726/05 67 TURP BPH Basalcell hyperplasia-Incomplete 
. 4728/05 45 TURP BPH  
. 4730/05 55 TURP BPH Stromal hyperplasia 
. 4752/05 73 TURP BPH Atypical adenomatous hyperplasia 
. 4753/05 57 TURP BPH Granulomatous prostatitis, Clearcell cribriform hyperplasia
. 4770/05 75 TURP BPH High grade PIN 
. 4847/05 82 TURP BPH Cystic atrophy 
. 4897/05 57 TURP BPH  
. 4898/05 65 TURP BPH  
. 4899/05 85 TURP BPH Chronic prostatitis, Low grade PIN 
. 4900/05 65 TURP BPH  
. 4912/05 72 Trucut Adenocarcinoma Grade III High grade PIN 
. 4986/05 75 TURP BPH Stromal nodule 
. 4987/05 70 TURP BPH Chronic prostatitis 
. 5043/05 64 TURP BPH Transitional cell metaplasia 
. 5044/05 60 TURP BPH Corpora amylacea 
. 5071/05 60 TURP BPH  
. 5073/05 72 TURP BPH  
. 5113/05 66 TURP Adenocarcinoma Grade IV Chronic prostatitis, High grade PIN 
. 5114/05 54 TURP BPH Chronic prostatitis 
. 5138/05 52 TURP BPH High grade PIN 
. 5139/05 65 TURP BPH  
. 5179/05 65 TURP BPH Low grade PIN 
. 5198/05 80 TURP BPH Chronic prostatitis 
. 5210/05 72 TURP BPH  
. 5224/05 86 TURP Adenocarcinoma grade I Low grade PIN 
. 5248/05 65 TURP BPH Chronic prostatitis 
. 5278/05 78 TURP BPH Stromal hyperplasia 
. 5337/05 60 TURP BPH Basalcell hyperplasia-complete, Chronic prostatitis 
. 5339/05 57 TURP BPH Chronic prostatitis 
. 5342/05 55 TURP Adenocarcinoma Grade III High grade PIN 
. 5366/05 50 TURP BPH Chronic prostatitis 
. 5368/05 53 TURP BPH  
. 5373/05 64 TURP BPH Low grade PIN 
o. Biopsy No. Age/Male Biopsy Specimen Histopathological Diagnosis Associated Lesions 
. 5376/05 54 TURP BPH Squamous metaplasia 
. 5453/05 67 TURP BPH Low grade PIN 
. 5480/05 61 TURP BPH Chronic prostatitis 
. 5551/05 65 TURP BPH  
. 5552/05 45 TURP BPH  
. 5556/05 70 TURP BPH High grade PIN 
. 5580/05 65 TURP BPH Cystic atrophy 
. 5602/05 56 TURP BPH High grade PIN 
. 5660/05 60 TURP BPH Chronic prostatitis 
. 5663/05 75 TURP BPH Chronic lymphocytic prostatitis, Abscess 
. 5664/05 60 TURP BPH Low grade PIN 
. 5706/05 70 TURP BPH Chronic prostatitis 
. 5766/05 75 Trucut Adenocarcinoma grade IV  
. 5792/05 50 TURP BPH  
. 5793/05 65 TURP BPH  
. 5799/05 65 TURP BPH  
. 5818/05 50 Trucut Only fibromuscular tissue  
. 5840/05 70 TURP Only few prostatic glands  
. 5880/05 80 TURP BPH  
. 5881/05 63 TURP BPH Chronic prostatitis 
. 5907/05 63 TURP BPH Chronic prostatitis 
. 5909A/05 82 TURP BPH  
. 5968/05 75 Trucut BPH Low grade PIN 
. 6036/05 70 TURP BPH  
. 6084/05 50 Trucut Tiny tissue - few glands  
. 6085/05 65 Trucut Tiny tissue - few glands  
. 6090/05 65 TURP BPH  
. 6269A/05 72 TURP BPH Cystic atrophy 
. 6301/05 82 TURP BPH Transitional cell metaplasia 
. 6323/05 45 TURP BPH  
. 6324/05 56 TURP BPH High grade PIN 
. 6326/05 65 Trucut BPH Chronic lymphocytic prostatitis 
. 6374/05 72 TURP BPH Basalcell hyperplasia-Incomplete 
. 6380/05 81 TURP BPH  
. 6409/05 66 TURP BPH Cystic atrophy 
. 6412/05 68 TURP BPH Stromal nodule 
. 6441/05 72 TURP BPH Low grade PIN 
. 6466/05 64 TURP BPH Chronic prostatitis 
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